Ascendis Pharma Files 6-K with SEC
Ticker: ASND · Form: 6-K · Filed: Dec 11, 2024 · CIK: 1612042
Sentiment: neutral
Topics: sec-filing, 6-k, disclosure
Related Tickers: ASND
TL;DR
Ascendis Pharma (ASND) filed a 6-K on 12/11/24, confirming 20-F annual reports and incorporating by reference into S-8 filings.
AI Summary
Ascendis Pharma A/S filed a Form 6-K on December 11, 2024, to report information as a foreign private issuer. The filing indicates that the company will file annual reports under Form 20-F. It also includes information regarding its registration statements on Form S-8.
Why It Matters
This filing provides routine updates and disclosures required for foreign private issuers, informing investors about the company's reporting status and incorporation by reference into existing registration statements.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Ascendis Pharma A/S (company) — Registrant
- 0001193125-24-275531 (filing_id) — Accession Number
- 20241211 (date) — Filing Date
- Form 6-K (document_type) — Filing Type
- Form 20-F (document_type) — Annual Report Form
- Form S-8 (document_type) — Registration Statement
FAQ
What is the primary purpose of this Form 6-K filing by Ascendis Pharma A/S?
The primary purpose is to report information as a foreign private issuer to the SEC, including its intention to file annual reports under Form 20-F and incorporation by reference into existing registration statements.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on December 11, 2024.
What type of annual report does Ascendis Pharma A/S file?
Ascendis Pharma A/S files its annual reports under cover of Form 20-F.
What is the company's principal executive office address as listed in the filing?
The company's principal executive office is located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.
Which registration statements are mentioned as incorporating this report by reference?
This report is incorporated by reference into registration statements on Form S-8 with Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, and 333-216883.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 15.8 · Accepted 2024-12-11 16:03:25
Key Financial Figures
- $129.67 — y and has an exercise price equal to US $129.67 per share, the closing price of the Ame
Filing Documents
- d880948d6k.htm (6-K) — 13KB
- d880948dex11.htm (EX-1.1) — 1202KB
- g880948dsp174.jpg (GRAPHIC) — 3KB
- g880948dsp175.jpg (GRAPHIC) — 3KB
- g880948dsp177.jpg (GRAPHIC) — 3KB
- g880948dsp178.jpg (GRAPHIC) — 3KB
- g880948dsp179.jpg (GRAPHIC) — 3KB
- g880948dsp180.jpg (GRAPHIC) — 5KB
- g880948dsp_24a.jpg (GRAPHIC) — 4KB
- g880948dsp_25a.jpg (GRAPHIC) — 8KB
- g880948dsp_25b.jpg (GRAPHIC) — 3KB
- g880948dsp_26a.jpg (GRAPHIC) — 6KB
- g880948dsp_33a.jpg (GRAPHIC) — 4KB
- g880948dsp_33b.jpg (GRAPHIC) — 8KB
- g880948dsp_34a.jpg (GRAPHIC) — 3KB
- g880948dsp_34b.jpg (GRAPHIC) — 6KB
- g880948page43.jpg (GRAPHIC) — 4KB
- g880948page44a.jpg (GRAPHIC) — 8KB
- g880948page44b.jpg (GRAPHIC) — 3KB
- g880948page45.jpg (GRAPHIC) — 6KB
- 0001193125-24-275531.txt ( ) — 1336KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: December 11, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer